• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Leukemic form of high-grade B-cell lymphoma (HGBL) in a very elderly patient with multiple comorbidities: effective treatment of a very rare subtype with a mini-R-da-EPOCH version.

作者信息

Belia Marina, Drandakis Ioannis, Lakiotaki Eleftheria, Arapaki Maria, Panitsas Fotios, Triantafyllou Evangelia-Fedra, Plata Eleni, Siakantaris Marina P, Angelopoulou Maria K, Korkolopoulou Penelope, Vassilakopoulos Theodoros P

机构信息

Department of Haematology and Bone Marrow Transplantation, School of Medicine, Laikon General Hospital, National and Kapodistrian University of Athens, Athens, Greece.

Department of Pathology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.

出版信息

Ann Hematol. 2023 Aug;102(8):2279-2282. doi: 10.1007/s00277-023-05214-5. Epub 2023 Apr 28.

DOI:10.1007/s00277-023-05214-5
PMID:37115296
Abstract
摘要

相似文献

1
Leukemic form of high-grade B-cell lymphoma (HGBL) in a very elderly patient with multiple comorbidities: effective treatment of a very rare subtype with a mini-R-da-EPOCH version.一名患有多种合并症的高龄患者的高级别B细胞淋巴瘤（HGBL）白血病形式：采用mini-R-da-EPOCH方案有效治疗一种非常罕见的亚型
Ann Hematol. 2023 Aug;102(8):2279-2282. doi: 10.1007/s00277-023-05214-5. Epub 2023 Apr 28.
2
Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study.剂量调整的EPOCH-R方案（依托泊苷、泼尼松、长春新碱、环磷酰胺、阿霉素和利妥昔单抗）用于治疗未经治疗的伴有MYC重排的侵袭性弥漫性大B细胞淋巴瘤：一项前瞻性、多中心、单臂2期研究。
Lancet Haematol. 2018 Dec;5(12):e609-e617. doi: 10.1016/S2352-3026(18)30177-7.
3
Venetoclax Boosts Benefits of R-EPOCH in Aggressive B-Cell Lymphomas.维奈托克增强 R-EPOCH 方案在侵袭性 B 细胞淋巴瘤中的获益。
Oncologist. 2020 Jul;25 Suppl 1(Suppl 1):S14-S15. doi: 10.1634/theoncologist.2020-0569. Epub 2020 Jun 26.
4
Long-term follow-up of dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in untreated patients with poor prognosis large B-cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group.剂量调整的EPOCH联合利妥昔单抗（DA-EPOCH-R）方案用于初治预后不良的大B细胞淋巴瘤患者的长期随访。西班牙PETHEMA研究组开展的一项II期研究。
Br J Haematol. 2015 Apr;169(2):188-98. doi: 10.1111/bjh.13273. Epub 2014 Dec 18.
5
Is Dose-Adjusted EPOCH-R Less Effective in Children Than Adults With Primary Mediastinal B-Cell Lymphoma?剂量调整后的EPOCH-R方案在儿童原发性纵隔B细胞淋巴瘤患者中比在成人患者中疗效更差吗？
J Clin Oncol. 2022 Jun 20;40(18):2063-2064. doi: 10.1200/JCO.21.02593. Epub 2022 Apr 4.
6
R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysis.利妥昔单抗联合环磷酰胺、阿霉素、长春新碱和泼尼松（R-CHOP）方案与剂量调整的利妥昔单抗联合依托泊苷、泼尼松、长春新碱、阿霉素和环磷酰胺（R-EPOCH）方案用于原发性纵隔B细胞淋巴瘤一线治疗的多中心分析
Br J Haematol. 2018 Feb;180(4):534-544. doi: 10.1111/bjh.15051. Epub 2017 Dec 19.
7
Dose-adjusted EPOCH-R is not superior to sequential R-CHOP/R-ICE as a frontline treatment for newly diagnosed primary mediastinal B-cell lymphoma: Results of a bi-center retrospective study.剂量调整的 EPOCH-R 方案并不优于序贯 R-CHOP/R-ICE 方案作为新诊断的原发性纵隔 B 细胞淋巴瘤的一线治疗：来自两项中心回顾性研究的结果。
Cancer Med. 2021 Dec;10(24):8866-8875. doi: 10.1002/cam4.4387. Epub 2021 Nov 24.
8
Venetoclax with dose-adjusted EPOCH-R as initial therapy for patients with aggressive B-cell lymphoma: a single-arm, multicentre, phase 1 study.维奈托克联合剂量调整的 EPOCH-R 方案作为侵袭性 B 细胞淋巴瘤患者的初始治疗：一项单臂、多中心、1 期研究。
Lancet Haematol. 2021 Nov;8(11):e818-e827. doi: 10.1016/S2352-3026(21)00273-8. Epub 2021 Oct 8.
9
Immunochemotherapy is the standard of care in elderly patients with diffuse large B-cell lymphoma.免疫化疗是老年弥漫性大B细胞淋巴瘤患者的标准治疗方法。
Blood. 2004 Sep 1;104(5):1584-5; author reply 1585-6. doi: 10.1182/blood-2004-04-1266.
10
Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303.剂量调整 EPOCH-R 与 R-CHOP 作为弥漫性大 B 细胞淋巴瘤一线治疗的比较：III 期联合组试验联盟/CALGB 50303 的临床结果。
J Clin Oncol. 2019 Jul 20;37(21):1790-1799. doi: 10.1200/JCO.18.01994. Epub 2019 Apr 2.

本文引用的文献

1
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee.成熟淋巴细胞肿瘤国际共识分类：临床咨询委员会报告。
Blood. 2022 Sep 15;140(11):1229-1253. doi: 10.1182/blood.2022015851.
2
Leukemic High Grade B Cell Lymphoma is Associated With MYC Translocation, Double Hit/Triple Hit Status, Transformation, and CNS Disease Risk: The Mayo Clinic Experience.白血病高级别 B 细胞淋巴瘤与 MYC 易位、双打击/三打击状态、转化以及 CNS 疾病风险相关：Mayo 诊所的经验。
Clin Lymphoma Myeloma Leuk. 2022 Aug;22(8):e815-e825. doi: 10.1016/j.clml.2022.04.009. Epub 2022 Apr 14.
3
Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma.
成人初治伯基特淋巴瘤采用剂量调整型EPOCH-R进行风险适应性治疗的多中心研究。
J Clin Oncol. 2020 Aug 1;38(22):2519-2529. doi: 10.1200/JCO.20.00303. Epub 2020 May 26.
4
Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303.剂量调整 EPOCH-R 与 R-CHOP 作为弥漫性大 B 细胞淋巴瘤一线治疗的比较：III 期联合组试验联盟/CALGB 50303 的临床结果。
J Clin Oncol. 2019 Jul 20;37(21):1790-1799. doi: 10.1200/JCO.18.01994. Epub 2019 Apr 2.
5
BCL-2 and MYC gain/amplification is correlated with central nervous system involvement in diffuse large B cell lymphoma at leukemic phase.BCL-2和MYC基因的获得/扩增与白血病期弥漫性大B细胞淋巴瘤的中枢神经系统受累相关。
BMC Med Genet. 2017 Feb 16;18(1):16. doi: 10.1186/s12881-017-0381-z.
6
The 2016 revision of the World Health Organization classification of lymphoid neoplasms.《世界卫生组织淋巴组织肿瘤分类（2016年修订版）》
Blood. 2016 May 19;127(20):2375-90. doi: 10.1182/blood-2016-01-643569. Epub 2016 Mar 15.
7
Low-intensity therapy in adults with Burkitt's lymphoma.成人伯基特淋巴瘤的低强度治疗。
N Engl J Med. 2013 Nov 14;369(20):1915-25. doi: 10.1056/NEJMoa1308392.
8
Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma.剂量调整的 EPOCH-利妥昔单抗治疗原发性纵隔 B 细胞淋巴瘤。
N Engl J Med. 2013 Apr 11;368(15):1408-16. doi: 10.1056/NEJMoa1214561.
9
Characteristics and outcomes of diffuse large B-cell lymphoma presenting in leukaemic phase.弥漫性大 B 细胞淋巴瘤白血病期的特征和结局。
Br J Haematol. 2012 Sep;158(5):608-14. doi: 10.1111/j.1365-2141.2012.09209.x. Epub 2012 Jul 4.
10
Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial.80 岁以上弥漫性大 B 细胞淋巴瘤患者的减毒免疫化疗方案（R-miniCHOP）：一项多中心、单臂、2 期临床试验。
Lancet Oncol. 2011 May;12(5):460-8. doi: 10.1016/S1470-2045(11)70069-9. Epub 2011 Apr 7.